{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response (CR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Tumor response is defined as the total number of eligible patients whose disease has a complete or partial response to GW786034 according to the RECIST criteria. Per RECIST v1.0 criteria:\n\nA Complete Response (CR) requires the disappearance of all target lesions.\n\nA Partial Response (PR) requires \\>=30% decrease in the sum of the longest diameter of target lesions from baseline measurement.\n\nAll patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.","groups":[{"description":"Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"paramType":"NUMBER","populationDescription":"All participants meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluated for response.","reportingStatus":"POSTED","timeFrame":"Participants will be evaluated every 8 weeks during treatment and up to 1 year after completion of treatment.","title":"Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST])","type":"PRIMARY","unitOfMeasure":"participants"}